Lantus and Perphenazine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lantus (insulin glargine recombinant) and Perphenazine (perphenazine). Common drug interactions include knee arthroplasty among females and gait disturbance among males.

The phase IV clinical study analyzes what interactions people have when they take Lantus and Perphenazine. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Perphenazine?

Perphenazine has active ingredients of perphenazine. It is often used in bipolar i disorder. eHealthMe is studying from 2,712 Perphenazine users. Check the latest studies of Perphenazine.



On Jul, 13, 2026

30 people who take Lantus and Perphenazine together, and have interactions are studied.

Lantus and Perphenazine drug interactions.

What are the common drug interactions of Lantus and Perphenazine, by gender? *:

female:

  1. Knee arthroplasty
  2. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  3. Oedema peripheral (superficial swelling)
  4. Proctitis (inflammation of the rectum and anus)
  5. Vomiting
  6. Abdominal pain upper
  7. Akathisia (a movement disorder characterized by a feeling of inner restlessness)
  8. Angina pectoris (chest pain due to ischemia of the heart muscle)
  9. Anxiety
  10. Aortic valve incompetence

male:

  1. Gait disturbance
  2. Dyspnoea (difficult or laboured respiration)
  3. Breath odour
  4. Breath sounds
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  6. Cardiac arrest
  7. Cataract (clouding of the lens inside the eye)
  8. Cerebral atrophy (decrement in size of brain)
  9. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  10. Decreased activity

What are the common drug interactions of Lantus and Perphenazine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Diabetes mellitus inadequate control
  2. Gait disturbance
  3. Muscular weakness (muscle weakness)
  4. Narcissistic personality disorder (a personality disorder in which the individual is described as being excessively preoccupied with issues of personal)
  5. Pain
  6. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  7. Psoriasis (immune-mediated disease that affects the skin)
  8. Scab (a hard coating on the skin formed during the wound healing)
  9. Schizoaffective disorder (a mental disorder characterized by disordered thought)
  10. Skin disorder (skin disease)

40-49:

  1. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  2. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  3. Confusional state
  4. Diarrhoea
  5. Nausea (feeling of having an urge to vomit)
  6. Vomiting
  7. Anuria (failure of the kidneys to produce urine)
  8. Blood glucose increased
  9. Diabetes with hyperosmolarity (diabetes with increasing blood glucose levels and dehydration)
  10. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

50-59:

  1. Oedema peripheral (superficial swelling)
  2. Oral disorder (mouth disease)
  3. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  4. Osteomyelitis (infection of bone)
  5. Pain in extremity
  6. Pain in jaw
  7. Pleural effusion (water on the lungs)
  8. Pneumonia
  9. Pulmonary embolism (blockage of the main artery of the lung)
  10. Purulence (containing pus)

60+:

  1. Dyspnoea (difficult or laboured respiration)
  2. Cardiac failure congestive
  3. Inflammatory bowel disease
  4. Injection site bruising
  5. Injection site haematoma (localized swelling filled with blood at injection site)
  6. Knee arthroplasty
  7. Oedema peripheral (superficial swelling)
  8. Proctitis (inflammation of the rectum and anus)
  9. Abdominal pain upper
  10. Akathisia (a movement disorder characterized by a feeling of inner restlessness)

What are the existing conditions these people have? *

  1. Pain: 8 people, 26.67%
  2. Metastases To Bone (cancer spreads to bone): 8 people, 26.67%
  3. Type 2 Diabetes: 7 people, 23.33%
  4. High Blood Pressure: 3 people, 10.00%
  5. Type 1 Diabetes: 2 people, 6.67%
  6. Tardive Dyskinesia (a disorder that involves involuntary movements): 2 people, 6.67%
  7. Psoriasis (immune-mediated disease that affects the skin): 2 people, 6.67%
  8. Multiple Myeloma (cancer of the plasma cells): 2 people, 6.67%
  9. Idiopathic Pulmonary Fibrosis (chronic lung disease): 2 people, 6.67%
  10. Depression: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and Perphenazine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lantus and Perphenazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Perphenazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lantus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Perphenazine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant and perphenazine (the active ingredients of Lantus and Perphenazine, respectively), and Lantus and Perphenazine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: